Journal of Bioequivalence & Bioavailability

Role of bioavailability and bioequivalence in drug design, discovery and development

4^th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R&D Summit

May 20-22, 2013 DoubleTree by Hilton, Beijing, China

Lalit Baregama

AcceptedAbstracts: J Bioequiv Availab

Abstract:

Role of bioavailability and bioequivalence in drug design, discovery and further development have emerged as critical issues in pharmacy and medicine during the last three decades. Concern about lowering health care costs has resulted in a tremendous increase in the use of generic drug products, which are available from more than one source. With the increasing availability and use of generic drug products, health care professionals are confronted with an ever-larger array of multisource products from which they must select those that are therapeutically equivalent. ? Role of BABE in drug design, discovery and late stage development: Evaluating major risks and limitations ? Strategy for improvement of BABE and meet the expectation of regulatory standards ? BABE: Future opportunities for generic and new drug development

Biography :

Over thirteen years of experience in Drug Discovery, Custom Pharmaceutical Services, Process Development, Business Development and Project Management with Global Pharmaceutical and Biotechnology companies like Wuxiapptec, Ranbaxy (Daiichi), Acoris (Hikal), Western Drugs and Cadila. He has worked on many drug discovery therapeutic areas like Asthma, COPD, Malaria, etc from proof of concept to market. He has been panelists and speakers in many executive summits and international conferences worldwide. He is an inventor of 28 patents, and 14 research publications are in his credit. He is M.Sc. in Organic Chemistry and Ph.D. in Medicinal Chemistry from ML Sukhadia University, India. Currently he is associated with Syngeny PharmaTech as CEO and President.